María‐Victoria Mateos

2002–2026 年に発表

別表記
María-Victoria Mateos · Maria-Victoria Mateos · Maria Victoria Mateos
367
論文数
55,969
被引用数
111
h 指数
341
i10 指数

被引用数

María‐Victoria Mateos の年別被引用数1986 年: 被引用 1 件1988 年: 被引用 7 件1989 年: 被引用 1 件1990 年: 被引用 1 件1993 年: 被引用 1 件2002 年: 被引用 1 件2003 年: 被引用 9 件2004 年: 被引用 4 件2005 年: 被引用 2 件2006 年: 被引用 7 件2007 年: 被引用 22 件2008 年: 被引用 59 件2009 年: 被引用 106 件2010 年: 被引用 132 件2011 年: 被引用 152 件2012 年: 被引用 115 件2013 年: 被引用 163 件2014 年: 被引用 197 件2015 年: 被引用 245 件2016 年: 被引用 313 件2017 年: 被引用 358 件2018 年: 被引用 330 件2019 年: 被引用 1,602 件2020 年: 被引用 2,093 件2021 年: 被引用 2,327 件2022 年: 被引用 1,903 件2023 年: 被引用 1,740 件2024 年: 被引用 3,486 件2025 年: 被引用 1,779 件2026 年: 被引用 43 件1987 年は被引用が無いため表示していません1991〜1992 年は被引用が無いため表示していません1994〜2001 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,229 件、この内訳の 23.1%中国: 引用元論文 924 件、この内訳の 6.6%ドイツ: 引用元論文 891 件、この内訳の 6.4%イタリア: 引用元論文 867 件、この内訳の 6.2%スペイン: 引用元論文 803 件、この内訳の 5.8%フランス: 引用元論文 780 件、この内訳の 5.6%イギリス: 引用元論文 772 件、この内訳の 5.5%オランダ: 引用元論文 481 件、この内訳の 3.5%カナダ: 引用元論文 454 件、この内訳の 3.3%オーストラリア: 引用元論文 383 件、この内訳の 2.7%ギリシャ: 引用元論文 383 件、この内訳の 2.7%ベルギー: 引用元論文 317 件、この内訳の 2.3%
0%23.1%その他 26.3%

分野

  • Medicine79.7%
  • Biochemistry, Genetics and Molecular Biology13.7%
  • Immunology and Microbiology3.5%
  • Computer Science0.7%
  • Engineering0.4%
  • Mathematics0.3%
  • その他1.7%

トピック

  • Multiple Myeloma Research and Treatments19.4%
  • Protein Degradation and Inhibitors7.9%
  • CAR-T cell therapy research5%
  • Peptidase Inhibition and Analysis4.3%
  • Cancer Treatment and Pharmacology2.6%
  • Lymphoma Diagnosis and Treatment2.6%
  • その他58.2%

共著者

全論文

検索で開く
  1. Teclistamab in Relapsed or Refractory Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jenna D. Goldberg, Rachel Kobos, Amrita Krishnan, Saad Z. Usmani - New England Journal of Medicine 2022 被引用: 1,114

  2. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wen-Ming Chen, Michèle Cavo, Jean‐Luc Harousseau, Suzanne Lentzsch, Jens Hillengaß, Antonio Palumbo, Alberto Órfão, S. Vincent Rajkumar, Jesús F. San Miguel, Hervé Avet‐Loiseau - The Lancet Oncology 2016 被引用: 2,995

  3. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert A. Kyle, Kenneth C. Anderson, Brian G.M. Durie, Jesús F. San Miguel - The Lancet Oncology 2014 被引用: 4,869

  4. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carolyn C. Jackson, Kaitlyn Connors, Katherine Li, Enrique Zudaire, Diana Chen, Jane Gilbert, Tzu‐Min Yeh, Sarah Nagle, Erika Florendo, Lida Pacaud, Nitin Patel, Simon J. Harrison, Hermann Einsele - New England Journal of Medicine 2023 被引用: 733

  5. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando López‐Guillermo, María‐Victoria Mateos, Elizabeth Macintyre, Ari Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano Pileri, Miguel Á. Piris, Barbara Pro, S. Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie H. Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz - Blood 2022 被引用: 1,506

  6. Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 被引用: 649

  7. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

    著者: , , , , , , , , , , , , , , , , - Annals of Oncology 2021 被引用: 820

  8. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2022 被引用: 270

  9. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld - Journal of Clinical Oncology 2022 被引用: 407

  10. Multiple myeloma

    著者: , , , , , , , - Nature Reviews Disease Primers 2017 被引用: 1,166

  11. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 178

  12. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Hermann Einsele, Philippe Moreau - Leukemia 2022 被引用: 240

  13. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet 2021 被引用: 312

  14. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Blood 2022 被引用: 201

  15. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

    著者: , , , , , , , , , , , , - Blood Cancer Journal 2023 被引用: 179

  16. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 被引用: 1,513

  17. Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

    著者: , , , , , , , , , , , , , , , , , , , , , , - Blood 2021 被引用: 161

  18. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 被引用: 984

  19. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Mario Boccadoro, Michèle Cavo, Javier de la Rubia Comos, Sosana Delimpasi, Meletios Α. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Façon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hájek, Güner Hayri Özsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Eirini Katodritou, Stefan Knop, Marie‐Christine Kyrtsonis, Juan José Lahuerta, Xavier Leleu, Carmen Martínez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique C. Minnema, Philippe Moreau, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlıvan, Luděk Pour, Henk Roerdink, Laura Rosinol Dacsh, Hans Salwender, Pieter Sonneveld, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tülin Tuğlular, Ali Ünal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman - The Lancet Oncology 2021 被引用: 327

  20. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Baldeep Wirk, Matthew T. Drake, Michèle Cavo, Juan José Lahuerta, Suzanne Lentzsch - The Lancet Oncology 2019 被引用: 496

  21. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Simon McNamara, Xiangdong Zhou, Maureen Nichols, Eric Lewis, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy–Ghanta, Joanna Opalińska, María-Victoria Mateos - New England Journal of Medicine 2024 被引用: 166

  22. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 87

  23. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2020 被引用: 275

  24. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 被引用: 151